Clinical Trial Update: A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) [Phase 3]

View source ↗

Summary

Phase 3 SURMOUNT-CN trial in Chinese participants without type 2 diabetes evaluated tirzepatide for obesity/overweight; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: COMPLETED | Results posted: 2024-01-19